Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Symbravo Patent Expiration

Symbravo is a drug owned by Axsome Therapeutics Inc. It is protected by 74 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 28, 2040. Details of Symbravo's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12128052 Pharmaceutical compositions comprising meloxicam
May, 2040

(15 years from now)

Active
US10702602 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11013806 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10722583 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10987358 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10729696 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10688102 Combination treatment for migraine and other pain
Apr, 2036

(11 years from now)

Active
US11865117 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10729697 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11617755 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10729773 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10517950 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11426414 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US9821075 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10029010 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10137131 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10195278 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10695429 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10265324 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11369684 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10695430 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10363312 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10688185 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10653777 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10583144 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11331323 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10561664 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10537642 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10369224 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10532101 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11285213 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10426839 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10471014 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11219626 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10471069 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10512692 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11207328 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10512693 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11135295 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11045549 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11020483 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11826370 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10940153 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11602563 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11806354 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11510927 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10933137 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11504429 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11471464 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10933136 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11801250 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10799588 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10780165 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10821181 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11759522 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10758618 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10918722 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11738085 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11013805 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11712441 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10905693 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11628173 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10894053 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11617791 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10821182 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11617756 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11607456 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11571428 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US11471465 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10780166 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10758617 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10058614 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10702535 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active
US10463736 Pharmaceutical compositions comprising meloxicam
Apr, 2036

(11 years from now)

Active


FDA has granted several exclusivities to Symbravo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Symbravo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Symbravo.

Exclusivity Information

Symbravo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Symbravo's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Symbravo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Symbravo's family patents as well as insights into ongoing legal events on those patents.

Symbravo's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Symbravo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 28, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Symbravo Generics:

There are no approved generic versions for Symbravo as of now.

Alternative Brands for Symbravo

There are several other brand drugs in the same treatment category as Symbravo. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Currax
Treximet Used for the treatment of migraines.
Eli Lilly And Co
Reyvow Used for managing acute migraine attacks.
Tonix Meds
Tosymra Used for managing acute migraine episodes.





About Symbravo

Symbravo is a drug owned by Axsome Therapeutics Inc. Symbravo uses Meloxicam; Rizatriptan Benzoate as an active ingredient. Symbravo was launched by Axsome in 2025.

Approval Date:

Symbravo was approved by FDA for market use on 30 January, 2025.

Active Ingredient:

Symbravo uses Meloxicam; Rizatriptan Benzoate as the active ingredient. Check out other Drugs and Companies using Meloxicam; Rizatriptan Benzoate ingredient

Dosage:

Symbravo is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG;EQ 10MG BASE TABLET Prescription ORAL